How to overcome diabetic retinopathy: Focusing on blood-retinal barrier

Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry

Volumn 12, Issue 2, 2012, Pages 110-117

  Jo, Dong Hyun ^a,b   Kim, Jin Hyoung ^a   Kim, Jeong Hun ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Angiogenesis; Blood retinal barrier; Diabetes; Diabetic retinopathy; Hypoxia; Inflammation; Oxidative stress; Retina; Tight junction; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; ALPHA TOCOPHEROL; BEVACIZUMAB; BEVASIRANIB; BROMFENAC; CANDESARTAN; CD18 ANTIGEN; CELECOXIB; CLAUDIN; DEXAMETHASONE; DEXTROMETHORPHAN; FENOFIBRATE; FLUOCINOLONE ACETONIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; MINOCYCLINE; NEPAFENAC; OCCLUDIN; PEGAPTANIB; PROTEIN ZO1; PROTEIN ZO2; RANIBIZUMAB; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; RUBOXISTAURIN; TRIAMCINOLONE; UNINDEXED DRUG; VASCULOTROPIN;

ARTICLE; BLOOD PRESSURE REGULATION; BLOOD RETINA BARRIER; DIABETIC RETINOPATHY; HUMAN; HYPOXIA; INFLAMMATION; LEUKOCYTE ADHERENCE; LOW LEVEL LASER THERAPY; NONHUMAN; OXIDATIVE STRESS; OXYGEN DISSOCIATION CURVE; OXYGEN TRANSPORT; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TIGHT JUNCTION; VITRECTOMY;

EID: 84860445042     PISSN: 18715222     EISSN: 18756115     Source Type: Journal    
DOI: 10.2174/187152212800389012     Document Type: Article

References (82)

1. Congdon, N.G.; Friedman, D.S.; Lietman, T. Important causes of visual impairment in the world today. JAMA, 2003, 290, 2057-2060.
2. Zhang, X.; Saaddine, J.B.; Chou, C.F.; Cotch, M.F.; Cheng, Y.J.; Geiss, L.S.; Gregg, E.W.; Albright, A.L.; Klein, B.E.; Klein, R. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA, 2010, 304, 649-656.
3. Kempen, J.H.; O'Colmain, B.J.; Leske, M.C.; Haffner, S.M.; Klein, R.; Moss, S.E.; Taylor, H.R.; Hamman, R.F. The prevalence of diabetic retinopathy among adults in the United States. Arch. Ophthalmol., 2004, 122, 552-563.
4. Penn, J.S.; Madan, A.; Caldwell, R.B.; Bartoli, M.; Caldwell, R.W.; Hartnett, M.E. Vascular endothelial growth factor in eye disease. Prog. Retin. Eye. Res., 2008, 27, 331-371.
5. Frank, R.N. Diabetic Retinopathy. N. Engl. J. Med., 2004, 350, 48-58.
6. Chen, E.; Looman, M.; Laouri, M.; Gallagher, M.; Van Nuys, K.; Lakdawalla, D.; Fortuny, J. Burden of illness of diabetic macular edema: literature review. Curr. Med. Res. Opin., 2010, 26, 1587-1597.
7. Kim, J.H.; Park, J.A.; Lee, S.W.; Kim, W.J.; Yu, Y.S.; Kim, K.W. Blood-neural barrier: intercellular communication at glio-vascular interface. J. Biochem. Mol. Biol., 2006, 39, 339-345.
8. Cunha-Vaz, J.G. Studies on the pathophysiology of diabetic retinopathy. The blood-retinal barrier in diabetes. Diabetes, 1983, 32(Suppl. 2), 20-27.
9. Abbott, N.J.; Ronnback, L.; Hansson, E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci., 2006, 7, 41-53.
10. Gardner, T.W.; Antonetti, D.A. Novel potential mechanisms for diabetic macular edema: leveraging new investigational approaches. Curr. Diab. Rep., 2008, 8, 263-269.
11. Cunha-Vaz, J.G.; Fonseca, J.R.; Abreu, J.F.; Ruas, M.A. A follow- up study by vitreous fluorophotometry of early retinal involvement in diabetes. Am. J. Ophthalmol., 1978, 86, 467-473.
12. Antonetti, D.A.; Barber, A.J.; Hollinger, L.A.; Wolpert, E.B.; Gardner, T.W. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J. Biol. Chem., 1999, 274, 23463-23467.
13. Harhaj, N.S.; Felinski, E.A.; Wolpert, E.B.; Sundstrom, J.M.; Gardner, T.W.; Antonetti, D.A. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Invest. Ophthalmol. Vis. Sci., 2006, 47, 5106-5115.
14. Kim, J.H.; Jun, H.O.; Yu, Y.S.; Kim, K.W. Inhibition of protein kinase C delta attenuates blood-retinal barrier breakdown in diabetic retinopathy. Am. J. Pathol., 2010, 176, 1517-1524.
15. Kim, J.H.; Yu, Y.S.; Cho, C.S.; Kim, K.W. Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy. J. Cereb. Blood. Flow. Metab., 2009, 29, 621-628.
16. Kim, J.H.; Yu, Y.S.; Min, B.H.; Kim, K.W. Protective effect of clusterin on blood-retinal barrier breakdown in diabetic retinopathy. Invest. Ophthalmol. Vis. Sci., 2010, 51, 1659-1665.
17. Frey, T.; Antonetti, D.A. Alterations to the blood-retinal barrier in diabetes: cytokines and reactive oxygen species. Antioxid. Redox. Signal, 2011, 15, 1271-1284.
18. Matter, K.; Balda, M.S. Signalling to and from tight junctions. Nat. Rev. Mol. Cell Biol., 2003, 4, 225-236.
19. Erickson, K.K.; Sundstrom, J.M.; Antonetti, D.A. Vascular permeability in ocular disease and the role of tight junctions. Angiogenesis, 2007, 10, 103-117.
20. Ditzel, J. Oxygen transport impairment in diabetes. Diabetes, 1976, 25, 832-838.
21. Jo, D.H.; Kim, J.H.; Kim, J.H. How to overcome retinal neuropathy: the fight against angiogenesis-related blindness. Arch. Pharm. Res., 2010, 33, 1557-1565.
22. Wilkinson-Berka, J.L. Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr. Pharm. Des., 2004, 10, 3331-3348.
23. Choi, Y.K.; Kim, J.H.; Kim, W.J.; Lee, H.Y.; Park, J.A.; Lee, S.W.; Yoon, D.K.; Kim, H.H.; Chung, H.; Yu, Y.S.; Kim, K.W. AKAP12 regulates human blood-retinal barrier formation by downregulation of hypoxia-inducible factor-1 alpha. J. Neurosci., 2007, 27, 4472-4481.
24. Josko, J.; Knefel, K. The role of vascular endothelial growth factor in cerebral oedema formation. Folia. Neuropathol, 2003, 41, 161-166.
25. Kaur, C; Sivakumar, V.; Yong, Z.; Lu, J.; Foulds, W.S.; Ling, E.A. Blood-retinal barrier disruption and ultrastructural changes in the hypoxic retina in adult rats: the beneficial effect of melatonin administration. J. Pathol, 2007, 212, 429-439.
26. Fischer, S.; Wobben, M.; Marti, H.H.; Renz, D.; Schaper, W. Hypoxia-induced hyperpermeability in brain microvessel endothelial cells involves VEGF-mediated changes in the expression of zonula occludens-1. Microvasc. Res., 2002, 63, 70-80.
27. Witt, K.A.; Mark, K.S.; Hom, S.; Davis, T.P. Effects of hypoxia reoxygenation on rat blood-brain barrier permeability and tight junctional protein expression. Am. J. Physiol. Heart Circ. Physiol, 2003, 285, H2820-H2831.
28. Chang, Y.H.; Chen, P.L.; Tai, M.C.; Chen, C.H.; Lu, D.W.; Chen, J.T. Hyperbaric oxygen therapy ameliorates the blood-retinal barrier breakdown in diabetic retinopathy. Clin. Experiment. Ophthalmol, 2006, 34, 584-589.
29. Joussen, A.M.; Poulaki, V.; Le, M.L.; Koizumi, K.; Esser, C; Janicki, H.; Schraermeyer, U.; Kociok, N.; Fauser, S.; Kirchhof, B.; Kern, T.S.; Adamis, A.P. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J., 2004, 18, 1450-1452.
30. Joussen, A.M.; Murata, T.; Tsujikawa, A.; Kirchhof, B.; Bursell, S.E.; Adamis, A.P. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am. J. Pathol, 2001, 158, 147-152.
31. Meleth, A.D.; Agron, E.; Chan, C.C.; Reed, G.F.; Arora, K.; Byrnes, G.; Csaky, K.G.; Ferris, F.L.; Chew, E.Y. Serum inflammatory markers in diabetic retinopathy. Invest. Ophthalmol. Vis. Sci., 2005, 46, 4295-4301.
32. Martiney, J.A.; Litwak, M.; Berman, J.W.; Arezzo, J.C.; Brosnan, C.F. Pathophysiologic effect of interleukin-1b in the rabbit retina. Am. J. Pathol, 1990, 137, 1411-1423.
33. Bamforth, S.D.; Lightman, S.L.; Greenwood, J. Interleukin-1 beta-induced disruption of the retinal vascular barrier of the central nervous system is mediated through leukocyte recruitment and histamine. Am. J. Pathol, 1997, 150, 329-340.
34. Sozen, T.; Tsuchiyama, R.; Hasegawa, Y.; Suzuki, H.; Jadhav, V.; Nishizawa, S.; Zhang, J.H. Role of Interleukin-1 p in Early Brain Injury After Subarachnoid Hemorrhage in Mice. Stroke, 2009, 40, 2519-2525.
35. Vinores, S.A.; Xiao, W.H.; Shen, J.; Campochiaro, P.A. TNF-alpha is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage. J. Neuroimmunol, 2007, 182, 73-79.
36. Giardino, I.; Edelstein, D.; Brownlee, M. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. J. Clin. Invest., 1996, 97, 1422-1428.
37. Nishikawa, T.; Edelstein, D.; Brownlee, M. The missing link: a single unifying mechanism for diabetic complications. Kidney Int. Suppl, 2000, 77, S26-S30.
38. Al-Shabrawey, M.; Bartoli, M.; El-Remessy, A.B.; Ma, G.; Matra-goon, S.; Lemtalsi, T.; Caldwell, R.W.; Caldwell, R.B. Role of NADPH oxidase and Stat3 in statin-mediated protection against diabetic retinopathy. Invest. Ophthalmol. Vis. Sci., 2008, 49, 3231-3238.
39. Al-Shabrawey, M.; Rojas, M.; Sanders, T.; Behzadian, A.; El-Remessy, A.; Bartoli, M.; Parpia, A.K.; Liou, G.; Caldwell, R.B. Role of NADPH oxidase in retinal vascular inflammation. Invest. Ophthalmol. Vis. Sci., 2008, 49, 3239-3244.
40. Ellis, E.A.; Guberski, D.L.; Somogyi-Mann, M.; Grant, M.B. Increased H2O2, vascular endothelial growth factor and receptors in the retina of the BBZ/Wor diabetic rat. Free Radic. Biol. Med., 2000, 28, 91-101.
41. Chronopoulos, A.; Tang, A.; Beglova, E.; Trackman, P.C.; Roy, S. High glucose increases lysyl oxidase expression and activity in retinal endothelial cells: mechanism for compromised extracellular matrix barrier function. Diabetes, 2010, 59, 3159-3166.
42. Usatyuk, P.V.; Natarajan, V. Role of mitogen-activated protein kinases in 4-hydroxy-2-nonenal-induced actin remodeling and barrier function in endothelial cells. J. Biol. Chem., 2004, 279, 11789-11797.
43. Bailey, T.A.; Kanuga, N.; Romero, I.A.; Greenwood, J.; Luthert, P.J.; Cheetham, M.E. Oxidative stress affects the junctional integrity of retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci., 2004, 45, 675-684.
44. Aiello, L.P.; Avery, R.L.; Arrigg, P.G.; Keyt, B.A.; Jampel, H.D.; Shah, S.T.; Pasquale, L.R.; Thieme, H.; Iwamoto, M.A.; Park, J.E.; Nguyen, H.V.; Aiello, L.M.; Ferrara, N.; King, G.L. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med., 1994, 331, 1480-1487.
45. Funatsu, H.; Yamashita, H.; Noma, H.; Mimura, T.; Yamashita, T.; Hori, S. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am. J. Ophthalmol., 2002, 133, 70-77.
46. Weis, S.M.; Cheresh, D.A. Pathophysiological consequences of VEGF-induced vascular permeability. Nature, 2005, 437, 497-504.
47. Kim, J.H.; Lee, Y.M.; Ahn, E.M.; Kim, K.W.; Yu, Y.S. Decursin inhibits VEGF-mediated inner blood-retinal barrier breakdown by suppression of VEGFR-2 activation. J. Cereb. Blood Flow Metab., 2009, 29, 1559-1567.
48. Lu, M.; Perez, V.L.; Ma, N.; Miyamoto, K.; Peng, H.B.; Liao, J.K.; Adamis, A.P. VEGF increases retinal vascular ICAM-1 expression in vivo. Invest. Ophthalmol. Vis. Sci., 1999, 40, 1808-1812.
49. Joussen, A.M.; Poulaki, V.; Qin, W.; Kirchhof, B.; Mitsiades, N.; Wiegand, S.J.; Rudge, J.; Yancopoulos, G.D.; Adamis, A.P. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am. J. Pathol., 2002, 160, 501-509.
50. Moore, T.C.; Moore, J.E.; Kaji, Y.; Frizzell, N.; Usui, T.; Poulaki, V.; Campbell, I.L.; Stitt, A.W.; Gardiner, T.A.; Archer, D.B.; Adamis, A.P. The role of advanced glycation end products in retinal microvascular leukostasis. Invest. Ophthalmol. Vis. Sci., 2003, 44, 4457-4464.
51. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med., 1993, 329, 977-986.
52. White, N.H.; Sun, W.; Cleary, P.A.; Danis, R.P.; Davis, M.D.; Hainsworth, D.P.; Hubbard, L.D.; Lachin, J.M.; Nathan, D.M. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch. Ophthalmol., 2008, 126, 1707-1715.
53. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ, 1998, 317, 703-713.
54. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology, 1991, 98, 766-785.
55. Newman, D.K. Surgical management of the late complications of proliferative diabetic retinopathy. Eye (Lond), 2010, 24, 441-449.
56. Cunningham, M.A.; Edelman, J.L.; Kaushal, S. Intravitreal steroids for macular edema: the past, the present, and the future. Surv. Ophthalmol., 2008, 53, 139-149.
57. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology, 2008, 115, 1447-1449, 1449. e1-10.
58. Beck, R.W.; Edwards, A.R.; Aiello, L.P.; Bressler, N.M.; Ferris, F.; Glassman, A.R.; Hartnett, E.; Ip, M.S.; Kim, J.E.; Kollman, C. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch. Ophthalmol., 2009, 127, 245-251.
59. Zechmeister-Koss, I.; Huic, M. Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: a systematic review. Br. J. Ophthalmol., 2012, 96, 167-178.
60. Manousaridis, K.; Talks, J. Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease? Br. J. Ophthalmol., 2012, 96, 179-184.
61. Wilkinson-Berka, J.L.; Tan, G.; Binger, K.J.; Sutton, L.; McMaster, K.; Deliyanti, D.; Perera, G.; Campbell, D.J.; Miller, A.G. Aliskiren reduces vascular pathology in diabetic retinopathy and oxygen-induced retinopathy in the transgenic (mRen-2)27 rat. Diabetologia, 2011, 54, 2724-2735.
62. Sjolie, A.K.; Klein, R.; Porta, M.; Orchard, T.; Fuller, J.; Parving, H.H.; Bilous, R.; Chaturvedi, N. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet, 2008, 372, 1385-1393.
63. Endo, N.; Kato, S.; Haruyama, K.; Shoji, M.; Kitano, S. Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta. Ophthalmol., 2010, 88, 896-900.
64. Flaxel, C.; Schain, M.B.; Hamon, S.C.; Francis, P.J. Prospective randomized controlled trial of combination ranibizumab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration: A Pilot Study. Retina, 2012, 32, 417-423.
65. Hariprasad, S.M.; Callanan, D.; Gainey, S.; He, Y.G.; Warren, K. Cystoid and diabetic macular edema treated with nepafenac 0.1%. J. Ocul. Pharmacol. Ther., 2007, 23, 585-590.
66. Kern, T.S.; Miller, C.M.; Du, Y.; Zheng, L.; Mohr, S.; Ball, S.L.; Kim, M.; Jamison, J.A.; Bingaman, D.P. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes, 2007, 56, 373-379.
67. McKeage, K.; Keating, G.M. Fenofibrate: a review of its use in dyslipidaemia. Drugs, 2011, 71, 1917-1946.
68. Simo, R.; Hernandez, C. Prevention and Treatment of Diabetic Retinopathy: Evidence from Large, Randomized Trials. The Emerging role of Fenofibrate. Rev. Recent. Clin. Trials, 2011, 7(1), 71-80.
69. Villarroel, M.; Garcia-Ramirez, M.; Corraliza, L.; Hernandez, C.; Simo, R. Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1beta by suppressing AMP-activated protein kinase (AMPK) activation. Diabetologia, 2011, 54, 1543-1553.
70. Sfikakis, P.P.; Grigoropoulos, V.; Emfietzoglou, I.; Theodossiadis, G.; Tentolouris, N.; Delicha, E.; Katsiari, C.; Alexiadou, K.; Hatz-iagelaki, E.; Theodossiadis, P.G. Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized,double-blind, placebo-controlled, crossover, 32-week study. Diabetes Care, 2010, 33, 1523-1528.
71. Wu, L.; Hernandez-Bogantes, E.; Roca, J.A.; Arevalo, J.F.; Barraza, K.; Lasave, A.F. Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group. Retina, 2011, 31, 298-303.
72. Aiello, L.P.; Clermont, A.; Arora, V.; Davis, M.D.; Sheetz, M.J.; Bursell, S.E. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest. Ophthalmol. Vis. Sci., 2006, 47, 86-92.
73. Aiello, L.P.; Vignati, L.; Sheetz, M.J.; Zhi, X.; Girach, A.; Davis, M.D.; Wolka, A.M.; Shahri, N.; Milton, R.C. Oral protein kinase c beta inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C beta Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C beta Inhibitor-Diabetic Retinopathy Study 2. Retina, 2011, 31, 2084-2094.
74. Krishnadev, N.; Forooghian, F.; Cukras, C.; Wong, W.; Saligan, L.; Chew, E.Y.; Nussenblatt, R.; Ferris, F., 3rd Meyerle, C. Subconjunctival sirolimus in the treatment of diabetic macular edema. Graefes Arch. Clin. Exp. Ophthalmol., 2011, 249, 1627-1633.
75. Forooghian, F.; Das, B. Anti-angiogenic effects of ribonucleic acid interference targeting vascular endothelial growth factor and hypoxia-inducible factor-1alpha. Am. J. Ophthalmol., 2007, 144, 761-768.
76. Zhang, M.; Zhang, J.; Yan, M.; Li, H.; Yang, C.; Yu, D. Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys. Mol. Vis., 2008, 14, 37-49.
77. Zhang, M.; Yu, D.; Yang, C.; Xia, Q.; Li, W.; Liu, B.; Li, H. The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm. Res., 2009, 26, 204-210.
78. Ip, M.S.; Bressler, S.B.; Antoszyk, A.N.; Flaxel, C.J.; Kim, J.E.; Friedman, S.M.; Qin, H. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina, 2008, 28, 919-930.
79. Pearson, P.A.; Comstock, T.L.; Ip, M.; Callanan, D.; Morse, L.S.; Ashton, P.; Levy, B.; Mann, E.S.; Eliott, D. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology, 2011, 118, 1580-1587.
80. Herrero-Vanrell, R.; Cardillo, J.A.; Kuppermann, B.D. Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema. Clin. Ophthalmol., 2011, 5, 139-146.
81. Boyer, D.S.; Faber, D.; Gupta, S.; Patel, S.S.; Tabandeh, H.; Li, X.Y.; Liu, C.C.; Lou, J.; Whitcup, S.M. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina, 2011, 31, 915-923.
82. Pazdro, R.; Burgess, J.R. The role of vitamin E and oxidative stress in diabetes complications. Mech. Ageing Dev., 2010, 131, 276-286.